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Introduction
Although the general methods of economic evaluation are well
established [1,2], it is often their detailed application that raises
methodological challenges. Most international guidelines for
economic evaluation, although appearing to be generic, have
been written with pharmaceuticals in mind [3]. For example,
they typically assume that randomized controlled trials (RCTs)
will be available for the assessment of relative treatment effect. In
this article, we argue that the economic evaluation of devices
raises additional challenges that international guidelines fre-
quently overlook.
Six ReasonsWhy Devices Are Different
The ﬁrst reason is the rather obvious one that many devices are
diagnostic. This raises two challenges, the ﬁrst being that the value
of improved diagnosis cannot be separated from the value of the
improvement in patient outcome resulting from the subsequent
treatment. This problem is not insurmountable, but makes the
economic evaluation of some devices much more complicated.
A further challenge in the evaluation of diagnostic devices is
that they often have multiple applications (e.g., a positron emis-
sion tomograpahy scanner). Although this is not unlike the
problem that drugs often have multiple indications, the device is
indivisible, which means that the overall value of the device is
some weighted average of its use in multiple applications. On the
other hand, being divisible, the value of a drug can be assessed in
each indication, and a judgment reached on each separately.
The second way in which devices are different is in the difﬁ-
culties in undertaking RCTs. By the time a drug reaches phase III
of clinical development, its dosage and route of administration
will typically be set. Therefore, although it is well known that the
efﬁcacy demonstrated in RCTs does not always translate into
practice, the results from trials provide a reasonable basis for
conducting an economic evaluation.
On the other hand, devices frequently undergo product modi-
ﬁcations, some of which may impact on efﬁcacy. In addition, there
is often a “learning curve” associated with the use of a device,
particularly those used in surgery. Therefore, an RCT comparing
a traditional surgical procedure with a new one involving a device
could well be demonstrating the difference between experience
with the old procedure versus inexperience with the new, rather
than differences between the procedures themselves. This issue
was evident in the Conventional versus Laparascopic-Assisted
Surgery In Patients with Colorectal Cancer (CLASICC) trial for
laparoscopic colorectal surgery, where outcomes in the laparo-
scopic arm were seen to improve over time as the surgeons gained
experience with the new technique [4].
All of this means that there is unlikely to be a substantial
“steady-state” period, during which the device could be evalu-
ated in an RCT. Therefore, it might be better to view the clinical
and economic evaluation of devices as an iterative approach,
with revisions being made to the estimates as more evidence is
gathered on effectiveness in actual use.
In addition, it is sometimes more difﬁcult to undertake
blinded studies with devices, with the risk that biases can be
introduced. For example, blinding can be difﬁcult (indeed unethi-
cal) if the alternative would have to be a sham procedure. Also,
patients are sometimes reluctant to enter RCTs if they are con-
cerned about being randomized to an invasive surgical proce-
dure, as opposed to a minimally invasive one.
The third reason why devices are different has already been
touched upon. Namely, the efﬁcacy of a device depends not only
on the device itself, but how it is used. Again, this is particularly
true for devices used in surgery, as the clinical outcome can
depend on the skill or experience of the surgeon. On the other
hand, drugs are a classic case of an “embodied technology.” That
is, as long as the drug is given in the right dose, the efﬁcacy relates
solely to the drug itself, not the person administering it.
The need to adjust for user characteristics further complicates
the design of RCTs and user performance is a potential con-
founder in the analysis of observational data on the efﬁcacy of
devices. Indeed, it might be preferable to undertake more multi-
center studies than is typical for all but the large phase III studies
of drugs. Whether these studies are randomized or not, the
statistical analysis would be more complicated, because it would
need to allow for treatment center effects. Taken in conjunction
with the points made above, it is clear that the design and
analysis of clinical studies of devices can be more challenging
than comparable studies of drugs.
The fourth way in which devices are different from drugs is
that implementation of a new therapy involving a device can
have wider economic implications. For example, there may be a
need for training, or more fundamentally, the local organiza-
tional context may be important for harnessing the improved
cost-effectiveness of a device. In the technology assessment report
for the National Institute for Health and Clinical Excellence
(NICE) on stapled hemorrhoidopexy, the authors noted that the
cost-effectiveness of the staple gun was likely to dependent on the
potential, in each location, to switch more patients to day case
surgery [5]. Such organizational adjustments are rarely examined
in economic evaluations. They can also be important in the case
of drugs (e.g., a new drug that increases potential for early
discharge from intensive care) [6], but are much less common.
The ﬁfth way in which devices are different from drugs is that
equivalent clinical evidence may not be available for all products,
making comparisons difﬁcult. Those undertaking economic evalu-
ations are often quick to “genericize” their recommendations,
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unless there is speciﬁc evidence to differentiate products. This
position is possibly driven from experience with pharmaceuticals,
where there is clinical evidence on each product, and where
assumptions about class effects are common, unless there is spe-
ciﬁc head-to-head trial evidence to the contrary. In addition, there
are now acceptable methods for making indirect or mixed treat-
ment comparisons, providing sufﬁcient clinical data are available
[7].
Class effect recommendations can also be made for medical
devices, but can sometimes be ﬂawed, or based on inadequate
evidence. For example, in 2003–2004 NICE issued positive guid-
ance through its technology appraisal program for Gynecare-
TVT (tension-free vaginal tape; a suburethral sling for stress
urinary incontinence) [8], and three branded devices for use as
second-generation endometrial-ablation technologies for heavy
menstrual bleeding [9]. Although there were not major differ-
ences in cost-effectiveness between the various devices, the tech-
nology appraisals did demonstrate differences in outcome that
may be important to some patients.
Nevertheless, when these treatments were incorporated into
NICE clinical guidelines in 2007 [10,11], the recommendations
for both slings and second-generation ablation technologies were
based on the assumption of a “class effect.” Both markets now
have many entrants, but little detailed review of the evidence for
each available device has been undertaken, to establish whether
there are important differences in clinical or cost-effectiveness.
Although approving new market entrants as quickly as pos-
sible may appear attractive as a method of increasing competi-
tion and therefore reducing costs to the provider, the practice
may be short sighted. At a minimum, it is a disincentive for
manufacturers to invest in research. This is in contrast to phar-
maceuticals, where evidence on efﬁcacy and safety is legally
required for every product. The incentive in the devices ﬁeld is to
be a fast follower and avoid the high costs of research attached to
being ﬁrst to market. Trials to demonstrate the role of devices in
clinical practice and longer term effectiveness are often over and
above what is needed to achieve a device Conformité Européene
(CE) mark, the requirement for market authorization in the
European Union. Extrapolating evidence from one device to
another may appear attractive in the short term, but this lower
hurdle for later market entrants could also impact patient safety,
as the longer-term follow-up data generated from the evidence-
base for one product may well not be attributable to all. Different
devices, though having the same clinical indication or outcome,
may have different physical properties, or even modes or action,
which should not be considered generic without adequate sup-
porting evidence.
The sixth way in which devices are different from drugs is
that prices are much more likely to change over time because of
the market entry of new products, or because of the ways in
which procurement takes place in many health-care systems. On
the other hand, in many countries, once the price of a drug is
negotiated, it is more likely to stay at or near that level until the
patent expires.
Indeed, because medical devices are often procured through
different mechanisms, more aligned with commodity products
than pharmaceuticals, the outcome of an economic evaluation
and health-care guidance based on formal technology appraisals
can directly inﬂuence pricing in the market place. For example, if
a technology assessment determines that clinical practice should
change to implement a new technology, it is also determining the
“old” technology is now obsolete, at least in that given popula-
tion. Then, because of the way medical devices are procured, the
price for the “obsolete” technology is rapidly driven down to
help create head room to fund the new “approved” technology.
If the price of the obsolete technology falls faster than the price
of the new technology, then the cost difference will increase,
changing the implied incremental cost-effectiveness ratio. This
could potentially change the decision, if this is based on a cost-
effectiveness threshold.
This issue arose in the recent reappraisal of drug-eluting
stents by NICE. The Appraisal Committee recognized that the
clinical effectiveness had not changed since the original guidance
was published [12], but noted the greater fall in bare metal stent
prices (as compared with those for drug-eluting stents) since the
original guidance. Increasing the incremental cost while not
changing the incremental effectiveness increased the incremental
cost-effectiveness ratio (ICER) to a level deemed not to be cost-
effective. Therefore, in the Appraisal Consultation Document,
the Committee recommended against the use of drug-eluting
stents [13]. This decision has subsequently been reversed in the
Final Appraisal Determination, though at the time of writing,
this has yet to be conﬁrmed as ﬁnal guidance to the NHS.
Of course, there are health-care markets (most notably the
United States) where special deals are negotiated for drugs and
where rebates are offered. In these markets, and more generally
for devices, an incremental cost-effectiveness ratio generated in a
single economic evaluation may not be very generalizable, as
prices are not stable over time or between locations.
Conclusions
Although the methods of economic evaluation can be equally
applied to drugs and devices in general, we have identiﬁed several
speciﬁc methodological issues that require more attention if reli-
able and informative evaluations of devices are to be conducted.
The views expressed are those of the authors themselves and are not
necessarily shared by their employing organizations.
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Introduction
The term “medical device” covers a wide range of technology.
According to the European Union (EU) directive 2007/47/EC, a
“medical device” is deﬁned as “any instrument, apparatus, appli-
ance, software, material or other article, whether used alone or in
combination, including the software intended by its manufacturer
to be used speciﬁcally for diagnostic and/or therapeutic purposes
and necessary for its proper application, intended by the manu-
facturer to be used for human beings for the purpose of diagnosis,
prevention, monitoring, treatment or alleviation of disease” [1].
Although medical devices and drugs both aim at restoring or
improving health, they are substantially different in their mode of
action. While drugs interact with biochemical pathways in the
human body, devices make use of a great diversity of actions and
reactions (e.g., radiation, heat, mechanical, electrical). In addi-
tion, devices may be used for both diagnostic and therapeutic
purposes. Thus, one may conclude that devices are fundamentally
different from drugs in nature and by deﬁnition.
The goal of health technology assessment (HTA) is to assess
the clinical and cost-effectiveness of existing and emerging
therapies—be those drugs or medical devices, or any other form
of medical technology—to inform the policy decisions of health-
care decision-makers on therapy access [2]. HTA is a two-stage
iterative process. First, a scientiﬁc assessment of the (clinical and
economic) evidence for a health technology is undertaken. Then,
based on this assessment, an appraisal of the evidence (together
with consideration of political, social, ethical factors) is made,
and a policy decision made, e.g., whether to fund or not to fund
the therapy in question. Increasingly, governments across the
world are mandating agencies such as the National Institute for
Health and Clinical Excellence (NICE) to issue national policy
guidelines on the use of drugs and medical devices based on such
a system of HTA and evidence-based appraisal.
Do the conceptual differences in drugs and medical devices
require a different framework of HTA or evidence-based
appraisal? In this article, we argue that although there are impor-
tant differences that need to be taken into account when assessing
the clinical and economic evidence base for medical devices—1)
the medical device licensing process; 2) the device-operator
interaction; and 3) the incremental innovation of medical
devices—these should not be seen as an obstacle to producing a
robust evidence base on the clinical and cost-effectiveness of
medical devices.
Medical Device Licensing
Drug licensing and market access approval by the Food and Drug
Administration (FDA) and international equivalents, such the
European Medicines Agency (EMEA) in Europe, require manu-
facturers to undertake randomized controlled (“phases II and
III”) trials to provide the regulator with robust evidence of their
drug’s efﬁcacy and safety. Nevertheless, the evidence hurdle for
licensing of medical devices is traditionally been much lower than
for pharmaceutical products [3]. For high-risk devices or new
devices for which there is no comparator product on the market
(class III devices), the FDA require manufacturers to submit a
premarket approval application, from which regulators deter-
mine whether there is sufﬁcient evidence of safety and effective-
ness for the intended uses [4]. In practice, this standard is often
met by small clinical trials in select groups of patients. The
studies often do not employ randomized designs, and the FDA
generally does not require manufacturers to collect long-term
efﬁcacy data [5]. HTA agencies and payers are therefore often
faced with the dilemma of assessing the clinical and cost-
effectiveness of medical devices in the face of absence or lack of
randomized controlled trial (RCT) evidence. For example, in two
recent technology appraisals by NICE of cochlear implants and
spinal cord stimulation for neuropathic back pain, manufactur-
ers submitted to NICE an evidence base of one and two RCTs,
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